Novo Nordisk Total Long Term Liabilities 2010-2024 | NVO

Novo Nordisk total long term liabilities for the quarter ending June 30, 2024 were $9.950B, a 102.31% increase year-over-year.

  • Novo Nordisk total long term liabilities for 2023 were $5.557B, a 6.55% increase from 2022.
  • Novo Nordisk total long term liabilities for 2022 were $5.215B, a 35.2% increase from 2021.
  • Novo Nordisk total long term liabilities for 2021 were $3.858B, a 122.36% increase from 2020.

Novo Nordisk Total Long Term Liabilities 2010-2024 | NVO

  • Novo Nordisk total long term liabilities for 2023 were $5.557B, a 6.55% increase from 2022.
  • Novo Nordisk total long term liabilities for 2022 were $5.215B, a 35.2% increase from 2021.
  • Novo Nordisk total long term liabilities for 2021 were $3.858B, a 122.36% increase from 2020.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$860.1B
Johnson & Johnson (JNJ)$400B
AbbVie (ABBV)$340.8B
Merck (MRK)$300.5B
AstraZeneca (AZN)$243.6B
Novartis AG (NVS)$237B
Pfizer (PFE)$168.6B
Sanofi (SNY)$145.6B
Innoviva (INVA)$1.2B